Nephrotoxicity and hematotoxicity associated with Lu-177 PSMA radioligand therapy in prostate cancer

Tarık Şengöz; Onur Cumhur Çimen; Ali Çelik; Aziz Gültekin; Fikri Selçuk Şimşek

Nephrotoxicity and hematotoxicity associated with Lu-177 PSMA radioligand therapy in prostate cancer

Abstract

Aims: Lutetium-177 (Lu-177) PSMA radioligand therapy (PRLT) is an effective treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Treatment-related nephrotoxicity and hematotoxicity can occur. In our study, we investigated the development of nephrotoxicity and hematotoxicity after Lu-177 PRLT applied to mCRPC patients in our department. Methods: All patients diagnosed with mCRPC who applied to our department between March 2018 and May 2025 and received at least 3 courses of Lu-177 PRLT were included in the study. The study was designed retrospectively. Patient information was obtained from patient treatment files and the hospital system. Patients were divided into two groups: those who received 3 courses of Lu-177 PRLT (group 1) and those who received ≥4 courses of Lu-177 PRLT (group 2). For the evaluation of hematotoxicity and nephrotoxicity, blood values were used in group 1 patients before treatment (on the day of the first cycle) and at the end of treatment (1 month after the third and final cycle); and in group 2 patients before treatment (on the day of the first cycle), interim (1 month after the third cycle), and at the end of treatment (1 month after the final cycle). Hematological and renal toxicity were determined according to the “Common Terminology Criteria for Adverse Events (CTCAE v5.0)”. Results: The study included 43 male patients (16 (37.3%) in group 1, 27 (62.7%) in group 2). The mean age was 69.74±7.86 years. In group 1 patients, post-treatment glomerular filtration rate (eGFR), red blood cells (RBC), hemoglobin (Hb), hematocrit (Htc), platelets (PLT), white blood cell count (WBC), and lymphocyte values were statistically significantly lower than pre treatment values, while creatinine values were higher. In Group 2 patients, post-treatment and interim eGFR, RBC, Hb, Htc, mean corpuscular hemoglobin volume (MCV), mean corpuscular hemoglobin (MCH), PLT, WBC, and lymphocyte values were statistically significantly lower than pre-treatment values, while creatinine levels were higher. When toxicity was assessed according to CTCAE v5.0, nephrotoxicity was detected in 2 patients (grade 2 and 3) (4.7%) and hematotoxicity in 3 patients (grade 2, 3 and 4) (7%) after treatment. No significant differences were found between the groups that received/did not receive chemotherapy before Lu-177 PRLT, and between pre- and post-treatment blood parameters. Conclusion: Although post-treatment deterioration in blood parameters indicating hematological and nephrological side effects was observed in patients diagnosed with mCRPC following Lu-177 PRLT, toxicity assessment according to CTCAE v5.0 revealed low levels of hematotoxicity and nephrotoxicity. Lu-177 PRLT is a safe treatment that can be applied with appropriate patient selection and monitoring.

Keywords

References

Global Cancer Observatory (accessed on 20th April 2024).
Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009;27(15):2450-2456. doi:10.1200/JCO.2008.19.9810
Calais J, Gafita A, Eiber M, et al. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 77Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. J Nucl Med. 2021;62(10):1440-1446. doi:10.2967/jnumed.121.261982.
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322
Hofman MS, Emmett L, Sandhu S, et al. [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021; 397(10276):797-804. doi:10.1016/S0140-6736(21)00237-3
Ells Z, Grogan TR, Czernin J, et al. Dosimetry of [177Lu] Lu-PSMA-targeted radiopharmaceutical therapies in patients with prostate cancer: a comparative systematic review and metaanalysis. J Nucl Med. 2024; 65(8):1264-1271. doi:10.2967/jnumed.124.267452
Santo G, Di Santo G, Sviridenko A, et al. Efficacy and safety of rechallenge with [177Lu] Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2024;52:354-365. doi:10.1007/s00259-024-06905-5
Hartrampf PH, Weinzierl FX, Serfling SE, et al. Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [177Lu] Lu-PSMA I&T. Cancers. 2022;14:647. doi.10.3390/cancers14030647

Steinhelfer L, Lunger L, Cala L, et al. Long-Term nephrotoxicity of 177Lu-PSMA radioligand therapy. J Nucl Med. 2024;65(1):79-84. doi:10.2967/jnumed.123.265986
Groener D, Nguyen CT, Baumgarten J, et al. Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. EJNMMI Res. 2021;11(1):61. doi:10.1186/s13550-021-00805-7
Sadaghiani MS, Sheikhbahaei S, Werner RA, et al. A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur Urol. 2021;80(1):82-94. doi:10.1016/j.eururo.2021.03.004
Hofman MS, Violet J, Hicks RJ, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825-833. doi:10.1016/S1470-2045(18)30198-0
Yadav MP, Ballal S, Sahoo RK, et al. Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR. 2019;213:275-285. doi: 10.2214/AJR.18.20845
Maffey-Steffan J, Scarpa L, Svirydenka A, et al. The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. Eur J Nucl Med Mol Imaging. 2020;47(3):695-712. doi:10.1007/s00259-019-04583-2
Parihar AS, Chopra S, Prasad V. Nephrotoxicity after radionuclide therapies. Transl Oncol. 2022;15(1):101295. doi:10.1016/j.tranon.2021.101295
Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109-122. doi:10.1016/0360-3016(91)90171-y
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Meyrick D, Gallyamov M, Sabarimurugan S, Falzone N, Lenzo N. Real-world data analysis of efficacy and survival after Lutetium-177 Labelled PSMA ligand therapy in metastatic castration-resistant prostate cancer. Target Oncol. 2021;16(3):369-380. doi:10.1007/s11523-021-00801-w
Kabasakal L, Toklu T, Yeyin N, et al. Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry. Mol Imaging Radionucl Ther. 2017;26:62-68. doi:10.4274/mirt.08760
Violet J, Sandhu S, Iravani A, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61:857-865. doi: 10.2967/jnumed.119. 236414
Fizazi K, Herrmann K, Krause BJ, et al. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(6):597-610. doi:10.1016/S1470-2045(23)00158-4
Heck MM, Tauber R, Schwaiger S, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75:920-926. doi:10.1016/j.eururo.2018.11.016
Carideo L, Meucci R, Campagna G, et al. Hematological side effects of 177Lu-DOTA-TATE therapy in patients with NENs. Hemato. 2025;6(1):1. doi:10.3390/hemato6010001

Details

Primary Language

English

Subjects

Clinical Oncology, Radiation Therapy

Journal Section

Research Article

Authors

Tarık Şengöz ^*
0000-0003-2621-7585
Türkiye

Onur Cumhur Çimen
0009-0000-3639-8282
Türkiye

Ali Çelik
0009-0008-0056-0039
Türkiye

Aziz Gültekin
0000-0002-0311-8077
Türkiye

Fikri Selçuk Şimşek
0000-0001-9906-0617
Türkiye

Publication Date

May 22, 2026

Submission Date

February 16, 2026

Acceptance Date

April 18, 2026

Published in Issue

Year 2026 Volume: 8 Number: 3

IZ

https://izlik.org/JA79YB29BH

Cite

RIS / Bibtex

APA

Şengöz, T., Çimen, O. C., Çelik, A., Gültekin, A., & Şimşek, F. S. (2026). Nephrotoxicity and hematotoxicity associated with Lu-177 PSMA radioligand therapy in prostate cancer. Anatolian Current Medical Journal, 8(3), 473-478. https://izlik.org/JA79YB29BH

AMA

1.Şengöz T, Çimen OC, Çelik A, Gültekin A, Şimşek FS. Nephrotoxicity and hematotoxicity associated with Lu-177 PSMA radioligand therapy in prostate cancer. Anatolian Curr Med J / ACMJ / acmj. 2026;8(3):473-478. https://izlik.org/JA79YB29BH

Chicago

Şengöz, Tarık, Onur Cumhur Çimen, Ali Çelik, Aziz Gültekin, and Fikri Selçuk Şimşek. 2026. “Nephrotoxicity and Hematotoxicity Associated With Lu-177 PSMA Radioligand Therapy in Prostate Cancer”. Anatolian Current Medical Journal 8 (3): 473-78. https://izlik.org/JA79YB29BH.

EndNote

Şengöz T, Çimen OC, Çelik A, Gültekin A, Şimşek FS (May 1, 2026) Nephrotoxicity and hematotoxicity associated with Lu-177 PSMA radioligand therapy in prostate cancer. Anatolian Current Medical Journal 8 3 473–478.

IEEE

[1]T. Şengöz, O. C. Çimen, A. Çelik, A. Gültekin, and F. S. Şimşek, “Nephrotoxicity and hematotoxicity associated with Lu-177 PSMA radioligand therapy in prostate cancer”, Anatolian Curr Med J / ACMJ / acmj, vol. 8, no. 3, pp. 473–478, May 2026, [Online]. Available: https://izlik.org/JA79YB29BH

ISNAD

Şengöz, Tarık - Çimen, Onur Cumhur - Çelik, Ali - Gültekin, Aziz - Şimşek, Fikri Selçuk. “Nephrotoxicity and Hematotoxicity Associated With Lu-177 PSMA Radioligand Therapy in Prostate Cancer”. Anatolian Current Medical Journal 8/3 (May 1, 2026): 473-478. https://izlik.org/JA79YB29BH.

JAMA

1.Şengöz T, Çimen OC, Çelik A, Gültekin A, Şimşek FS. Nephrotoxicity and hematotoxicity associated with Lu-177 PSMA radioligand therapy in prostate cancer. Anatolian Curr Med J / ACMJ / acmj. 2026;8:473–478.

MLA

Şengöz, Tarık, et al. “Nephrotoxicity and Hematotoxicity Associated With Lu-177 PSMA Radioligand Therapy in Prostate Cancer”. Anatolian Current Medical Journal, vol. 8, no. 3, May 2026, pp. 473-8, https://izlik.org/JA79YB29BH.

Vancouver

1.Tarık Şengöz, Onur Cumhur Çimen, Ali Çelik, Aziz Gültekin, Fikri Selçuk Şimşek. Nephrotoxicity and hematotoxicity associated with Lu-177 PSMA radioligand therapy in prostate cancer. Anatolian Curr Med J / ACMJ / acmj [Internet]. 2026 May 1;8(3):473-8. Available from: https://izlik.org/JA79YB29BH